CLASSIFICATION: GHRH Analogue
ACNE: No
WATER RETENTION: No
HBR: No
HEPATOTOXICITY: No
AROMATIZATION: No
MANUFACTURER: Beligas
WAREHOUSE: International Warehouse 3
SUBSTANCE: GHRH Peptide
Introducing CJC-1295, a cutting-edge synthetic analogue of growth hormone-releasing hormone (GHRH) composed of 30 amino acids. Extensive research highlights its remarkable capability to enhance the secretion of growth hormone and IGF-1, all while preserving the natural pulsatile release of growth hormone.
This powerful peptide is often paired with Ipamorelin, as CJC-1295 offers targeted GHRH stimulation. While Ipamorelin also elevates growth hormone levels, it uniquely avoids the appetite stimulation and spikes in cortisol, acetylcholine, prolactin, and aldosterone associated with other peptides. Together, CJC-1295 and Ipamorelin provide a harmonious and effective solution.
Stimulating the Pituitary Gland:
- Promotes heightened growth hormone and IGF-1 secretion without increasing prolactin levels
- Supports increased body weight and growth via enhanced protein synthesis
- Accelerates muscle growth and improves bone density
- Boosts immune function and cognitive abilities
- Enhances memory retention and collagen production
- Facilitates fat loss and cellular repair
Key Benefits of CJC-1295:
CJC-1295 is also recognized for its ability to promote deep, restorative sleep, essential for muscle recovery, cognitive function, and overall rejuvenation.
Produced in the hypothalamus, GHRH?s short half-life of just a few minutes limits its effectiveness in stimulating growth hormone release from the pituitary gland.
Understanding CJC-1295 Forms:
The active segment of GHRH comprises the first 29 amino acids and is available as Sermorelin. CJC-1295 was developed to extend its half-life to 30 minutes. This was further improved with the addition of DAC (Drug Affinity Complex), which binds to blood protein albumin, prolonging its half-life to approximately 8 days. This results in CJC-1295 + DAC, while a non-DAC variant simulates a more natural nightly growth hormone spike.
The extended half-life of CJC-1295 + DAC means injections may only be needed once or twice a week. However, this prolonged presence can lead to steady stimulation of growth hormone release, which may not mimic natural physiological patterns and could lessen the amplitude of growth hormone pulses, reducing tissue stimulation.
To mitigate these effects, it?s advisable to take "hormone holidays" lasting three months every three to six months, allowing the pituitary gland to recover. During these breaks, Sermorelin is recommended over CJC-1295 + DAC.
Safety Considerations:
Implementing "hormone holidays" can also help lower the risk of developing growth hormone resistance, a theoretical concern stemming from potential antibody formation or a decrease in growth hormone receptor availability. However, no long-term studies have conclusively verified these risks.
Potential Side Effects of CJC-1295:
Users may experience reactions at the injection site, including irritation, redness, swelling, pain, or itching, as well as headaches, nausea, diarrhea, vasodilation (which may lead to flushing or transient hypotension), and abdominal discomfort.